Werewolf Therapeutics Inc. announced new preclinical data expanding its PREDATOR® platform at the 2025 Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, held November 5-9, 2025. The company presented first-in-kind real-time pharmacokinetic data demonstrating that WTX-124 is selectively activated in tumors while sparing healthy tissue in a mouse tumor model. Additional findings included the development of the novel INDUCER™ T Cell Engager Platform, which utilizes a differentiated masking approach to mitigate systemic toxicities, and a sequential dosing regimen of INDUKINE™ molecules that showed potent antitumor activity with improved safety in preclinical studies. The results were presented at the SITC meeting.